schedule an appointment Georgia Eye Partners Surgeon Among First in U.S. to Trial Breakthrough Glaucoma Technology
Posted by: Georgia Eye Partners in News and Updates
Dr. Gagan Sawhney of Georgia Eye Partners recently joined an elite group of ophthalmologists as one of the first five surgeons in the nation to trial the newly FDA-cleared VIA360™ Surgical System from New World Medical. This cutting-edge technology, unveiled in February 2025, represents a significant advancement in glaucoma surgery—bringing greater precision and control to canaloplasty and trabeculotomy procedures.
The VIA360™ system features ActiveInject™ Technology, a breakthrough innovation that enables ophthalmic surgeons to deliver viscoelastic fluid with exceptional precision. Its 360-degree microcatheter allows for comprehensive canal dilation using both forward and tangential flow, offering a patient-specific approach to treatment.
“What stood out to me most about the VIA360 Surgical System is its precision. The ActiveInject Technology delivers viscoelastic exactly when and where it’s needed, while the 360-degree microcatheter allows for thorough canal dilation,” said Dr. Sawhney. “Beyond the innovation, I’m continually impressed by New World Medical’s commitment to global eye health. They’ve supported my charity cases for years, helping expand access to sight-saving care for patients who need it most.”
Georgia Eye Partners has long been recognized as a leader in ophthalmic care across the Southeast. Known for its fellowship-trained specialists and focus on clinical innovation, the practice continues to stay at the forefront of emerging technologies. Dr. Sawhney’s involvement in this early trial underscores the practice’s dedication to improving surgical outcomes and broadening access to high-quality eye care.
To learn more about the VIA360™ Surgical System, visit www.via360surgicalsystem.com/. For more on Georgia Eye Partners and its physicians, visit https://www.gaeyepartners.com.
